01923nas a2200349   4500000000100000008004100001260001700042653002700059653001200086653002600098653002400124653002300148653003000171653002000201653001100221653001200232653002600244653002600270653002500296653001700321100001800338700001500356700001400371700001300385700001200398245007900410300001100489490000700500050003200507520102000539022001401559       1991                            d  c1991 Jul-Dec10aAdjuvants, Immunologic10aAnimals10aAntibodies, Bacterial10aAntigens, Bacterial10aBacterial Proteins10aCytotoxicity, Immunologic10aHLA-DR Antigens10aHumans10aleprosy10aLymphocyte Activation10aMacrophage Activation10aMycobacterium leprae10aPhagocytosis1 aMahadevan P R1 aRobinson P1 aVermani M1 aPardhy A1 aJoshi S00aDelipidified cell components of Mycobacterium leprae and its applications.  a371-870 v63  aInfolep Library - available3 a<p>Delipidified cell components (DCC) of Mycobacterium leprae obtained as an insoluble material consist of several proteins. This preparation, DCC, has ability to differentially bind to sera from lepromatous leprosy patients and antibodies to this complex get reduced as patients improve under chemotherapy. The antigenic complex has no ability to bind to proteins of sera from normal healthy individuals or tuberculoid leprosy patients. The DCC is antigenic and is recognised by immune deficient cells of lepromatous leprosy patients, leading to lymphocyte proliferation, production of Interleukin II and interferon gamma, and resulting in activation of the phagocytes to initiate killing of endocytosed M.leprae through reactive oxygen intermediates, primarily superoxide. The DCC has also immunomodulatory properties to protect mice against M.leprae infection. Experiments with mice and isolated peripheral blood cells from patients have indicated the probable molecular mechanism of immunomodulation by DCC.</p>  a0254-9395